Peptides

CordenPharma has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide CDMO with facilities in North Augusta, South Carolina (USA) and Shanghai (China).With the acquisition, CordenPharma broadens its peptide API development and manufacturing capabilities for complex peptide programs.

CordenPharma, a global CDMO leader in the manufacture of Drug Substances (APIs) for complex modalities (such as peptides, GalNAc, lipids, etc.), Lipid NanoParticles (LNPs) containing xRNA / xDNA, and injectable Drug Products, and Certest, a Spanish company focused on the development of new products with special emphasis in Drug Delivery with LNPs and API synthesis, have signed a partnership agreement.

Consortium formed between WACKER & CordenPharma has officially entered the pandemic readiness state as of 1 June 2024 to produce 80 million vaccine doses within a short time, if needed. Following a successful expansion and qualification phase, the companies are now in a stand-by readiness phase for at least five years. Should the need arise, the German government will contact the developer of the specific mRNA vaccine required and WACKER & CordenPharma will then jointly produce this mRNA vaccine in line with the highest pharmaceutical quality standards.

Basel, Switzerland – 6 May 2025 > CordenPharma is proud to announce that the Science-Based Targets initiative (SBTi) has officially approved the group’s near-term greenhouse gas (GHG) emission reduction targets. Following a two-year carbon footprint measurement process resulting in a submission of the targets in November 2024, the SBTi’s Target Validation Team has confirmed that the group’s ambition is in conformance with the SBTi Standards and Guidance.

CordenPharma has submitted its near-term greenhouse gas (GHG) emission reduction targets to the Science Based Targets initiative (SBTi) for approval, marking a major step in its climate action commitments.
 

CordenPharma, the CDMO specialising in APIs, lipid excipients, and drug products, signs a new billion dollar contract to expand its manufacturing capabilities. 

The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. 

In this interview from CPHI Frankfurt 2022, we speak to Dr Michael Quirmbach of CordenPharma about his role as President and CEO and what CordenPharma is bringing to the pharma industry.

All Your Injectables Needs in One Location

Peptide synthesis has traditionally relied on Classic Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), each with inherent limitations. LPPS, while efficient in reagent use, is only suitable for short peptides and requires tedious isolation steps. SPPS, widely adopted, is solvent-intensive and presents challenges in large-scale manufacturing. TAG-Assisted Peptide Synthesis (TAPS) combines the best of both worlds, offering an innovative hybrid approach that integrates LPPS and SPPS advantages. This method employs a TAG-anchor molecule, which solubilizes the growing peptide in an organic solution, allowing for multiple elongation cycles without isolation, significantly improving  efficiency. TAPS presents a highly efficient, sustainable, and scalable alternative to traditional peptide synthesis.